Based on this, we further validated the clinical relevance of ACTN1 protein expression using immunohistochemistry and found that ACTN1 expression is negatively correlated with grade II/III gliomas patient prognosis (Fig. 10D–G). Here, ACTN1 is linked to central nervous system cancer.